Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA
Summary Previous studies have suggested that infant vaccinations may reduce the risk of subsequent childhood leukaemia. Vaccination histories were compared in 439 children (ages 0–14) diagnosed with acute lymphoblastic leukaemia (ALL) in nine Midwestern and Mid-Atlantic states (USA) between 1 Januar...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1999-09, Vol.81 (1), p.175-178 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 1 |
| container_start_page | 175 |
| container_title | British journal of cancer |
| container_volume | 81 |
| creator | Groves, F D Gridley, G Wacholder, S Shu, X O Robison, L L Neglia, J P Linet, M S |
| description | Summary
Previous studies have suggested that infant vaccinations may reduce the risk of subsequent childhood leukaemia. Vaccination histories were compared in 439 children (ages 0–14) diagnosed with acute lymphoblastic leukaemia (ALL) in nine Midwestern and Mid-Atlantic states (USA) between 1 January 1989 and 30 June 1993 and 439 controls selected by random-digit dialing and individually matched to cases on age, race and telephone exchange. Among matched pairs, similar proportions of cases and controls had received at least one dose of oral poliovirus (98%), diphtheria–tetanus–pertussis (97%), and measles–mumps–rubella (90%) vaccines. Only 47% of cases and 53% of controls had received any
Haemophilus influenzae
type b (Hib) vaccine (relative risk (RR) = 0.73; 95% confidence interval (CI) 0.50–1.06). Although similar proportions of cases (12%) and controls (11%) received the polysaccharide Hib vaccine (RR = 1.13; 95% CI 0.64–1.98), more controls (41%) than cases (35%) received the conjugate Hib vaccine (RR = 0.57; 95% CI 0.36–0.89). Although we found no relationship between most infant vaccinations and subsequent risk of childhood ALL, our findings suggest that infants receiving the conjugate Hib vaccine may be at reduced risk of subsequent childhood acute lymphoblastic leukemia. Further studies are needed to confirm this association and, if confirmed, to elucidate the underlying mechanism. |
| doi_str_mv | 10.1038/sj.bjc.6690668 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374362</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70031224</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-ab9ff3ac3a6c2eef461fbbf552eddf12469b88369dda75417e2ff8b75eb094723</originalsourceid><addsrcrecordid>eNp1kc1r3DAQxUVpabZprz0WHUpv3ujDluxLIYSmDQQKSXMWI1mK5cjSVrID-e_jZZc2PfQ0DPObN8N7CH2kZEsJb8_KuNWj2QrRESHaV2hDG84q2jL5Gm0IIbIiHSMn6F0p49p2pJVv0QkldSsFJxt0cxUdxBk_gjE-wuxTLBhij7MvDzg5bAYf-iGlHoNZZovD07Qbkg5QZm9wsMsD2MkD9hHPg8V3t-fv0RsHodgPx3qK7i6__br4UV3__H51cX5dmbpp5gp05xwHw0EYZq2rBXVau6Zhtu8dZbXodNty0fU9yKam0jLnWi0bq0lXS8ZP0deD7m7Rk-2NjXOGoHbZT5CfVAKv_p1EP6j79KgYlzUXe4EvR4Gcfi-2zGryxdgQINq0FCUJ4ZSxegW3B9DkVEq27s8RStQ-BlVGtcagjjGsC59evvYCP_i-Ap-PABQDwWWIxpe_3F6maVbs7ICVdRLvbVZjWnJcXf3f5We1YaMc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70031224</pqid></control><display><type>article</type><title>Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA</title><source>MEDLINE</source><source>PMC (PubMed Central)</source><source>SpringerLink Journals</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Groves, F D ; Gridley, G ; Wacholder, S ; Shu, X O ; Robison, L L ; Neglia, J P ; Linet, M S</creator><creatorcontrib>Groves, F D ; Gridley, G ; Wacholder, S ; Shu, X O ; Robison, L L ; Neglia, J P ; Linet, M S</creatorcontrib><description>Summary
Previous studies have suggested that infant vaccinations may reduce the risk of subsequent childhood leukaemia. Vaccination histories were compared in 439 children (ages 0–14) diagnosed with acute lymphoblastic leukaemia (ALL) in nine Midwestern and Mid-Atlantic states (USA) between 1 January 1989 and 30 June 1993 and 439 controls selected by random-digit dialing and individually matched to cases on age, race and telephone exchange. Among matched pairs, similar proportions of cases and controls had received at least one dose of oral poliovirus (98%), diphtheria–tetanus–pertussis (97%), and measles–mumps–rubella (90%) vaccines. Only 47% of cases and 53% of controls had received any
Haemophilus influenzae
type b (Hib) vaccine (relative risk (RR) = 0.73; 95% confidence interval (CI) 0.50–1.06). Although similar proportions of cases (12%) and controls (11%) received the polysaccharide Hib vaccine (RR = 1.13; 95% CI 0.64–1.98), more controls (41%) than cases (35%) received the conjugate Hib vaccine (RR = 0.57; 95% CI 0.36–0.89). Although we found no relationship between most infant vaccinations and subsequent risk of childhood ALL, our findings suggest that infants receiving the conjugate Hib vaccine may be at reduced risk of subsequent childhood acute lymphoblastic leukemia. Further studies are needed to confirm this association and, if confirmed, to elucidate the underlying mechanism.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6690668</identifier><identifier>PMID: 10487630</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adolescent ; Bacterial Capsules ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Chickenpox Vaccine ; Child ; Child, Preschool ; Diphtheria-Tetanus-Pertussis Vaccine - adverse effects ; Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use ; Drug Resistance ; Epidemiology ; Female ; Haemophilus Vaccines - adverse effects ; Haemophilus Vaccines - therapeutic use ; Hematologic and hematopoietic diseases ; Humans ; Immunization Schedule ; Infant ; Infant, Newborn ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Measles Vaccine - adverse effects ; Measles Vaccine - therapeutic use ; Measles-Mumps-Rubella Vaccine ; Medical sciences ; Molecular Medicine ; Mumps Vaccine - adverse effects ; Mumps Vaccine - therapeutic use ; Oncology ; Polysaccharides, Bacterial - adverse effects ; Polysaccharides, Bacterial - therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - etiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - prevention & control ; Regular ; regular-article ; Risk Factors ; Rubella Vaccine - adverse effects ; Rubella Vaccine - therapeutic use ; United States - epidemiology ; Vaccines, Combined - adverse effects ; Vaccines, Combined - therapeutic use ; Viral Vaccines - adverse effects ; Viral Vaccines - therapeutic use</subject><ispartof>British journal of cancer, 1999-09, Vol.81 (1), p.175-178</ispartof><rights>The Author(s) 1999</rights><rights>1999 INIST-CNRS</rights><rights>Copyright © 1999 Cancer Research Campaign 1999 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-ab9ff3ac3a6c2eef461fbbf552eddf12469b88369dda75417e2ff8b75eb094723</citedby><cites>FETCH-LOGICAL-c455t-ab9ff3ac3a6c2eef461fbbf552eddf12469b88369dda75417e2ff8b75eb094723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374362/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374362/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1906655$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10487630$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Groves, F D</creatorcontrib><creatorcontrib>Gridley, G</creatorcontrib><creatorcontrib>Wacholder, S</creatorcontrib><creatorcontrib>Shu, X O</creatorcontrib><creatorcontrib>Robison, L L</creatorcontrib><creatorcontrib>Neglia, J P</creatorcontrib><creatorcontrib>Linet, M S</creatorcontrib><title>Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Summary
Previous studies have suggested that infant vaccinations may reduce the risk of subsequent childhood leukaemia. Vaccination histories were compared in 439 children (ages 0–14) diagnosed with acute lymphoblastic leukaemia (ALL) in nine Midwestern and Mid-Atlantic states (USA) between 1 January 1989 and 30 June 1993 and 439 controls selected by random-digit dialing and individually matched to cases on age, race and telephone exchange. Among matched pairs, similar proportions of cases and controls had received at least one dose of oral poliovirus (98%), diphtheria–tetanus–pertussis (97%), and measles–mumps–rubella (90%) vaccines. Only 47% of cases and 53% of controls had received any
Haemophilus influenzae
type b (Hib) vaccine (relative risk (RR) = 0.73; 95% confidence interval (CI) 0.50–1.06). Although similar proportions of cases (12%) and controls (11%) received the polysaccharide Hib vaccine (RR = 1.13; 95% CI 0.64–1.98), more controls (41%) than cases (35%) received the conjugate Hib vaccine (RR = 0.57; 95% CI 0.36–0.89). Although we found no relationship between most infant vaccinations and subsequent risk of childhood ALL, our findings suggest that infants receiving the conjugate Hib vaccine may be at reduced risk of subsequent childhood acute lymphoblastic leukemia. Further studies are needed to confirm this association and, if confirmed, to elucidate the underlying mechanism.</description><subject>Adolescent</subject><subject>Bacterial Capsules</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Chickenpox Vaccine</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Haemophilus Vaccines - adverse effects</subject><subject>Haemophilus Vaccines - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunization Schedule</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Measles Vaccine - adverse effects</subject><subject>Measles Vaccine - therapeutic use</subject><subject>Measles-Mumps-Rubella Vaccine</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Mumps Vaccine - adverse effects</subject><subject>Mumps Vaccine - therapeutic use</subject><subject>Oncology</subject><subject>Polysaccharides, Bacterial - adverse effects</subject><subject>Polysaccharides, Bacterial - therapeutic use</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - etiology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - prevention & control</subject><subject>Regular</subject><subject>regular-article</subject><subject>Risk Factors</subject><subject>Rubella Vaccine - adverse effects</subject><subject>Rubella Vaccine - therapeutic use</subject><subject>United States - epidemiology</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - therapeutic use</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - therapeutic use</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1r3DAQxUVpabZprz0WHUpv3ujDluxLIYSmDQQKSXMWI1mK5cjSVrID-e_jZZc2PfQ0DPObN8N7CH2kZEsJb8_KuNWj2QrRESHaV2hDG84q2jL5Gm0IIbIiHSMn6F0p49p2pJVv0QkldSsFJxt0cxUdxBk_gjE-wuxTLBhij7MvDzg5bAYf-iGlHoNZZovD07Qbkg5QZm9wsMsD2MkD9hHPg8V3t-fv0RsHodgPx3qK7i6__br4UV3__H51cX5dmbpp5gp05xwHw0EYZq2rBXVau6Zhtu8dZbXodNty0fU9yKam0jLnWi0bq0lXS8ZP0deD7m7Rk-2NjXOGoHbZT5CfVAKv_p1EP6j79KgYlzUXe4EvR4Gcfi-2zGryxdgQINq0FCUJ4ZSxegW3B9DkVEq27s8RStQ-BlVGtcagjjGsC59evvYCP_i-Ap-PABQDwWWIxpe_3F6maVbs7ICVdRLvbVZjWnJcXf3f5We1YaMc</recordid><startdate>19990901</startdate><enddate>19990901</enddate><creator>Groves, F D</creator><creator>Gridley, G</creator><creator>Wacholder, S</creator><creator>Shu, X O</creator><creator>Robison, L L</creator><creator>Neglia, J P</creator><creator>Linet, M S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990901</creationdate><title>Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA</title><author>Groves, F D ; Gridley, G ; Wacholder, S ; Shu, X O ; Robison, L L ; Neglia, J P ; Linet, M S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-ab9ff3ac3a6c2eef461fbbf552eddf12469b88369dda75417e2ff8b75eb094723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Bacterial Capsules</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Chickenpox Vaccine</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Haemophilus Vaccines - adverse effects</topic><topic>Haemophilus Vaccines - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunization Schedule</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Measles Vaccine - adverse effects</topic><topic>Measles Vaccine - therapeutic use</topic><topic>Measles-Mumps-Rubella Vaccine</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Mumps Vaccine - adverse effects</topic><topic>Mumps Vaccine - therapeutic use</topic><topic>Oncology</topic><topic>Polysaccharides, Bacterial - adverse effects</topic><topic>Polysaccharides, Bacterial - therapeutic use</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - etiology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - prevention & control</topic><topic>Regular</topic><topic>regular-article</topic><topic>Risk Factors</topic><topic>Rubella Vaccine - adverse effects</topic><topic>Rubella Vaccine - therapeutic use</topic><topic>United States - epidemiology</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - therapeutic use</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Groves, F D</creatorcontrib><creatorcontrib>Gridley, G</creatorcontrib><creatorcontrib>Wacholder, S</creatorcontrib><creatorcontrib>Shu, X O</creatorcontrib><creatorcontrib>Robison, L L</creatorcontrib><creatorcontrib>Neglia, J P</creatorcontrib><creatorcontrib>Linet, M S</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Groves, F D</au><au>Gridley, G</au><au>Wacholder, S</au><au>Shu, X O</au><au>Robison, L L</au><au>Neglia, J P</au><au>Linet, M S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1999-09-01</date><risdate>1999</risdate><volume>81</volume><issue>1</issue><spage>175</spage><epage>178</epage><pages>175-178</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Summary
Previous studies have suggested that infant vaccinations may reduce the risk of subsequent childhood leukaemia. Vaccination histories were compared in 439 children (ages 0–14) diagnosed with acute lymphoblastic leukaemia (ALL) in nine Midwestern and Mid-Atlantic states (USA) between 1 January 1989 and 30 June 1993 and 439 controls selected by random-digit dialing and individually matched to cases on age, race and telephone exchange. Among matched pairs, similar proportions of cases and controls had received at least one dose of oral poliovirus (98%), diphtheria–tetanus–pertussis (97%), and measles–mumps–rubella (90%) vaccines. Only 47% of cases and 53% of controls had received any
Haemophilus influenzae
type b (Hib) vaccine (relative risk (RR) = 0.73; 95% confidence interval (CI) 0.50–1.06). Although similar proportions of cases (12%) and controls (11%) received the polysaccharide Hib vaccine (RR = 1.13; 95% CI 0.64–1.98), more controls (41%) than cases (35%) received the conjugate Hib vaccine (RR = 0.57; 95% CI 0.36–0.89). Although we found no relationship between most infant vaccinations and subsequent risk of childhood ALL, our findings suggest that infants receiving the conjugate Hib vaccine may be at reduced risk of subsequent childhood acute lymphoblastic leukemia. Further studies are needed to confirm this association and, if confirmed, to elucidate the underlying mechanism.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>10487630</pmid><doi>10.1038/sj.bjc.6690668</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1999-09, Vol.81 (1), p.175-178 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374362 |
| source | MEDLINE; PMC (PubMed Central); SpringerLink Journals; Nature; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Bacterial Capsules Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Chickenpox Vaccine Child Child, Preschool Diphtheria-Tetanus-Pertussis Vaccine - adverse effects Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use Drug Resistance Epidemiology Female Haemophilus Vaccines - adverse effects Haemophilus Vaccines - therapeutic use Hematologic and hematopoietic diseases Humans Immunization Schedule Infant Infant, Newborn Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Measles Vaccine - adverse effects Measles Vaccine - therapeutic use Measles-Mumps-Rubella Vaccine Medical sciences Molecular Medicine Mumps Vaccine - adverse effects Mumps Vaccine - therapeutic use Oncology Polysaccharides, Bacterial - adverse effects Polysaccharides, Bacterial - therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology Precursor Cell Lymphoblastic Leukemia-Lymphoma - etiology Precursor Cell Lymphoblastic Leukemia-Lymphoma - prevention & control Regular regular-article Risk Factors Rubella Vaccine - adverse effects Rubella Vaccine - therapeutic use United States - epidemiology Vaccines, Combined - adverse effects Vaccines, Combined - therapeutic use Viral Vaccines - adverse effects Viral Vaccines - therapeutic use |
| title | Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T13%3A21%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infant%20vaccinations%20and%20risk%20of%20childhood%20acute%20lymphoblastic%20leukaemia%20in%20the%20USA&rft.jtitle=British%20journal%20of%20cancer&rft.au=Groves,%20F%20D&rft.date=1999-09-01&rft.volume=81&rft.issue=1&rft.spage=175&rft.epage=178&rft.pages=175-178&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6690668&rft_dat=%3Cproquest_pubme%3E70031224%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70031224&rft_id=info:pmid/10487630&rfr_iscdi=true |